REFRACTORY INDOLENT NON-HODGKIN LYMPHOMA
Clinical trials for REFRACTORY INDOLENT NON-HODGKIN LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY INDOLENT NON-HODGKIN LYMPHOMA trials appear
Sign up with your email to follow new studies for REFRACTORY INDOLENT NON-HODGKIN LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New 'Triple-Target' immune therapy enters human testing for tough blood cancers
Disease control Recruiting nowThis early-stage trial is testing the safety and best dose of a new type of CAR-T cell therapy. The therapy uses a patient's own immune cells, modified to attack three different markers (CD19, CD20, CD22) found on cancer cells. It is for adults with certain advanced blood cancers…
Matched conditions: REFRACTORY INDOLENT NON-HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Disease control
Last updated Apr 04, 2026 06:51 UTC
-
Cancer trial aims to slash radiation time and side effects
Disease control Recruiting nowThis study is testing whether a shorter, lower-dose course of radiation therapy works as well as the standard, longer course for treating slow-growing non-Hodgkin lymphoma. The main goal is to see if the shorter treatment causes fewer immediate side effects while still controllin…
Matched conditions: REFRACTORY INDOLENT NON-HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Mar 10, 2026 12:53 UTC